Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Paratek Pharmaceuticals Inc PRTK

Healthcare Industrials Business Services
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult... see more

Recent & Breaking News (NDAQ:PRTK)

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire September 4, 2018

Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference

GlobeNewswire August 29, 2018

FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline

GlobeNewswire August 8, 2018

Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections

GlobeNewswire August 8, 2018

Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results

GlobeNewswire August 2, 2018

Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018

GlobeNewswire July 23, 2018

Paratek Announces FDA Advisory Committee Date for Omadacycline

GlobeNewswire June 20, 2018

Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus at ASM Microbe 2018

GlobeNewswire June 11, 2018

Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018

GlobeNewswire June 7, 2018

Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

PR Newswire June 6, 2018

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire June 1, 2018

Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

Benzinga.com  May 19, 2018

Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results

GlobeNewswire May 9, 2018

Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire May 1, 2018

Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen

Benzinga.com  April 25, 2018

Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

PR Newswire April 20, 2018

Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024

GlobeNewswire April 19, 2018

Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024

GlobeNewswire April 18, 2018

Paratek Appoints Rolf K. Hoffman to Company’s Board of Directors

GlobeNewswire April 13, 2018

Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018

GlobeNewswire April 12, 2018